NCT06774040View on ClinicalTrials.gov

Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

March 31, 2027

Study Completion Date

May 31, 2027

Conditions
Peripheral Arterial Disease
Interventions
DRUG

Etribnabdione 25 mg BID

The trial will start with the lower dose. When the 12 patients have been treated for 3 months and the PK and safety data are evaluated by the regulatory authority, the Sponsor and the site investigators, the high dose (50 mg BID) will be released.

DRUG

Etribnabdione 50 mg BID

The treatment will start when the regulatory authority, the sponsor and the site investigators have reviewed the low dose safety and pharmacokinetics data.

Trial Locations (1)

14014

Hospital Universitario Reina Sofía, Córdoba

All Listed Sponsors
lead

VivaCell Biotechnology España

INDUSTRY